Precision Medicine

Following a $25M fundraise, former WA Health Secretary Dr. Shah joins Jaan Health, signaling a new era for AI-driven chronic disease management.

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

For the 24th straight year, nurses top Gallup's ethics poll, but this enduring trust masks a profession in crisis, battling burnout and staff shortages.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

As its single-dose glaucoma therapy nears trials, Diorasis adds a seasoned dealmaker to its board, signaling a strategic shift toward market entry.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.